SCHEMBL3620029

SCHEMBL3620029

O=c1[nH]ccc2c3[nH]c(-c4c(F)cccc4F)nc3c3ccc(Br)cc3c12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 4/20 0.64
JAK3 P52333 3/20 0.64
PTGES O14684 14/20 0.60
CHEK1 O14757 3/20 0.54
JAK1 P23458 2/20 0.51
TYK2 P29597 2/20 0.51
PIM1 P11309 2/20 0.46
CSNK2A2 P19784 1/20 0.46
CSNK2B P67870 1/20 0.46
PIM3 Q86V86 1/20 0.46
PIM2 Q9P1W9 1/20 0.46
IKBKB O14920 1/20 0.45
MAPK13 O15264 1/20 0.45
DAPK3 O43293 1/20 0.45
PRKD3 O94806 1/20 0.45
FYN P06241 1/20 0.45
RET P07949 1/20 0.45
HCK P08631 1/20 0.45
PDGFRB P09619 1/20 0.45
FGFR1 P11362 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3619724 0.93 JAK2 (0.76) JAK2JAK3PTGESJAK1TYK2
SCHEMBL3617183 0.92 JAK2 (0.56) JAK2JAK3PTGESCHEK1JAK1
SCHEMBL5760532 0.89 JAK2 (0.79) JAK2JAK3PTGESCHEK1JAK1
SCHEMBL3620595 0.85 JAK2 (0.62) JAK2JAK3PTGESCHEK1JAK1
SCHEMBL3618732 0.84 JAK2 (0.60) JAK2JAK3PTGESCHEK1JAK1
SCHEMBL3621532 0.83 JAK2 (0.59) JAK2JAK3PTGESCHEK1JAK1
SCHEMBL3611211 0.83 JAK2 (0.62) JAK2JAK3PTGESCHEK1JAK1
SCHEMBL5761216 0.82 JAK2 (0.92) JAK2JAK3PTGESCHEK1JAK1
SCHEMBL3621182 0.82 JAK2 (0.58) JAK2JAK3PTGESCHEK1JAK1
SCHEMBL3620280 0.82 JAK2 (0.58) JAK2JAK3PTGESCHEK1JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1801189-B1 Synergistic lubricating oil composition containing a mixture of a benzo[b]perhydroheterocyclic arylamine and a diarylamine CHEVRON ORONITE CO (US) 2012-11-07 EP claimed
EP-2077315-B1 Lubricating oil compositions containing a tetraalkyl-napthalene-1,8 diamine antioxidant and a diarylamine antioxidant CHEVRON ORONITE CO (US) 2012-10-31 EP claimed
US-20090306071-A1 Inhibitors of Janus Kinases MERCK SHARP & DOHME LLC 2009-12-10 US claimed
EP-2032141-B1 INHIBITORS OF JANUS KINASES MERCK SHARP & DOHME (US) 2012-10-31 EP disclosed
US-7763634-B2 Inhibitors of janus kinases MERCK & CO., INC. (US) 2010-07-27 US disclosed
US-7763634-B2 Inhibitors of janus kinases MERCK & CO., INC. (US) 2010-07-27 US disclosed
US-7763634-B2 Inhibitors of janus kinases MERCK & CO., INC. (US) 2010-07-27 US disclosed
US-20090306071-A1 Inhibitors of Janus Kinases MERCK SHARP & DOHME LLC 2009-12-10 US disclosed
US-20090306071-A1 Inhibitors of Janus Kinases MERCK SHARP & DOHME LLC 2009-12-10 US disclosed
US-20090306071-A1 Inhibitors of Janus Kinases MERCK SHARP & DOHME LLC 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306071-A1 Inhibitors of Janus Kinases JAK2, JAK3, JAK1 JAK2 1/4885JAK3 2/4885PTGES 2420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.